Johnson & Johnson’s single-dose vaccine has received an Emergency Use Authorization (EUA) from the federal government, making it the third COVID-19 vaccine available for use in the United States.
The Johnson & Johnson vaccine is the first single-dose vaccine against COVID-19. It can be stored in a refrigerator for months, making it easier to distribute without the need for ultra-cold storage.
“Having access to a third highly effective COVID-19 vaccine is a game-changing development for Oregonians,” said Paul Cieslak, M.D, medical director for communicable diseases and immunization, OHA Public Health Division. “We believe this vaccine is effective against the virus, and a one-dose regimen will allow us to vaccinate more Oregonians more quickly.”
The process for the Johnson & Johnson vaccine review and approval was the same as it was for the Moderna and Pfizer vaccines. The company submitted its application for EUA on Feb. 4.
In its review of Johnson & Johnson’s application, the FDA reported the vaccine was 66% effective for moderate to severe/critical COVID-19 in all groups across all regions studied starting at 28 days after vaccination. The observed efficacy in the United States was 72%. The clinical trial involved 43,783 participants in the United States, Latin America, Brazil and South Africa.
“The best thing is that this one-dose vaccine was 85% efficacious in preventing severe COVID-19,” Dr. Cieslak said.
Reported vaccine side effects include pain at the injection site, mild to moderate headache, fatigue and muscle aches.
This article first appeared in the March 1, 2021 issue of Oregon Coronavirus Update.